Immunome plans three INDs by 1Q 2025; closes Zentalis ADC license, Atreca antibody purchase

Immunome Inc.

Zentalis ADC license: $35M upfront (cash+stock), $275M milestones, mid-to-high single digit royalties for ROR1 ADC IM-1021.
Atreca antibody purchase: $5.5M cash upfront, $7M milestones for over 25 preclinical antibodies; closing subject to shareholder approval.
IND filings planned for 1Q 2025 for FAP radioligand therapy, ROR1 ADC (IM-1021), and IL-38 immunotherapy.
AbbVie collaboration: $30M upfront, up to $70M platform payments, $120M per target milestones, $150M per target sales milestones.
Preclinical data shows IM-1021 superior to MK-2140 in TNBC model; proprietary payload outperforms Enhertu in HER2-low model.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.